case_images: PMC11208475_01
case_images: Treatment process and follow-up of metastatic pancreatic cancer patient through treatment periods. The patient received different treatments at different times. BITAP immunization was applied along with standard of care chemotherapy (A). Immunogenicity testing of manufactured peptides by IVS- (B) and Ex-Vivo (C) IFN-gamma ELISPOT assays. CA19-9 marker levels of the patient throughout the treatment (D). Immuno-monitoring of the patient during the treatment (E) MRI scan was performed before and approximately three and six months after the start of BITAP immunization (F).
case_images: fimmu-15-1414737-g001.jpg
case_images: PMC11208475_01_fimmu-15-1414737-g001.jpg
case_images: f1
case_images: Therefore, new chemotherapy regimens were initiated, with Gemcitabine and Erlotinib administered from March 2022 to September 2022, followed by a switch to Onivyde starting in October 2022 ( Figure 1A ).